Skip to main content

Featured

Market Futures Slip as Geopolitical Tensions Weigh on Sentiment

  U.S. stock futures edged lower early Thursday as investors attempted to extend Wednesday’s rebound but remained cautious amid ongoing conflict in the Middle East. Futures tied to the Dow Jones Industrial Average fell about 0.4%, while S&P 500 and Nasdaq 100 futures slipped roughly 0.2% each. The pullback followed a strong regular session in which all three major indexes posted gains, with the Dow snapping a three‑day losing streak.  The overnight weakness reflects persistent market sensitivity to geopolitical developments. Escalating tensions involving the U.S., Israel, and Iran continue to drive volatility across asset classes, with traders closely watching oil prices and inflation implications. Recent sessions have seen markets swing sharply as headlines shift, underscoring the fragile balance between economic fundamentals and geopolitical risk.  Despite the cautious tone, Wednesday’s rally showed that investors are still willing to buy into dips—particularl...

article

Pharmacare in Canada: A Dream or a Reality?

 


The fate of Canada's pharmacare plan is uncertain as the federal government faces challenges in implementing a universal drug coverage program, even if a bill to create one passes in Parliament. Bill C-213, the Canada Pharmacare Act, aims to establish a national framework for pharmacare that would ensure all Canadians have access to prescription drugs based on their medical needs, not their ability to pay. 

However, the bill does not specify how the program would be funded, administered or negotiated with the provinces and territories, leaving many questions unanswered about the feasibility and cost-effectiveness of pharmacare. Some experts and stakeholders have expressed doubts about whether Ottawa has the political will, the constitutional authority and the fiscal capacity to deliver on its promise of pharmacare, especially in the wake of the COVID-19 pandemic that has strained the health care system and the public purse.

Comments